Home Cart Sign in  
Chemical Structure| 668467-91-2 Chemical Structure| 668467-91-2

Structure of LDN-57444
CAS No.: 668467-91-2

Chemical Structure| 668467-91-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

LDN-57444 is a reversible, competitive, site-directed inhibitor of ubiquitin C-terminal hydrolase L1 (UCH-L1), with an IC50 of 0.88 μM and a Ki of 0.40 μM. It also suppresses UCH-L3 activity with an IC50 of 25 μM.

Synonyms: Ubiquitin C-terminal Hydrolase L1 Inhibitor; UCH-L1 Inhibitor

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of LDN-57444

CAS No. :668467-91-2
Formula : C17H11Cl3N2O3
M.W : 397.64
SMILES Code : O=C1N(CC2=CC(Cl)=CC=C2Cl)C3=C(C=C(Cl)C=C3)/C1=N/OC(C)=O
Synonyms :
Ubiquitin C-terminal Hydrolase L1 Inhibitor; UCH-L1 Inhibitor
MDL No. :MFCD09037562

Safety of LDN-57444

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • UCH

    UCH-L3, IC50:25 μM

    UCH-L1, IC50:0.4 μM

In Vitro:

Cell Line
Concentration Treated Time Description References
chondrocytes 8 µM 1 day LDN-57444 inhibited UCHL1, reversed the increase in LC3B expression under hypoxic conditions, and increased the proportion of apoptotic cells. PMC10555477
rat HSC >10 μM 24 hours Inhibition of UCHL1 significantly reduced the proliferation of hepatic stellate cells in response to PDGFBB stimulation PMC4866442
human HSC >10 μM 24 hours Inhibition of UCHL1 significantly reduced the proliferation of human hepatic stellate cells PMC4866442
Murine bone marrow mesenchymal stem cells 10 μM 24 hours LDN57444 pretreatment significantly enhanced the immunosuppressive effects of murine bone marrow mesenchymal stem cells on T cell proliferation and upregulated iNOS expression. PMC5913136
Human bone marrow mesenchymal stem cells 20 μM 24 hours LDN57444 pretreatment enhanced the immunosuppressive effects of human bone marrow mesenchymal stem cells on T cell proliferation and upregulated IDO expression. PMC5913136
hippocampal neurons 10 µM 24 hours To investigate the effects of UCH-L1 inhibition on synaptic structure and monomeric ubiquitin levels. Results showed that LDN significantly reduced monomeric ubiquitin levels and caused dramatic alterations in synaptic protein distribution and spine morphology. PMC2748938
NP69 and NP69-LMP1 cells 3 μM 24 hours Inhibition of UCH-L1 DUB activity, reducing migration of LMP1-positive cells PMC6696221
SH-SY5Y cells 10 μM 3 days LDN57444 pretreatment significantly inhibited RA-induced neuronal differentiation in SH-SY5Y cells, characterized by decreased neurite outgrowth and reduced expression of neural differentiation markers. PMC6203192
293 cells 3 μM 48 hours Inhibition of UCH-L1 DUB activity, reducing HIF-1α levels in exosomes PMC6696221
HSC-3 cells 3 μM 48 hours Inhibition of UCH-L1 DUB activity, reducing motility of HSC-3 cells PMC6696221
Cochlear supporting cells 5 µM 5 days LDN-57444 significantly increased Brn3c mRNA levels and promoted the transdifferentiation of supporting cells into hair cells. PMC11083094
SK-N-BE (2) cells 10 μM 7 days LDN57444 pretreatment significantly inhibited RA-induced neuronal differentiation in SK-N-BE (2) cells, characterized by decreased neurite outgrowth and reduced expression of neural differentiation markers. PMC6203192
NEPC cells (TD-NEPC) 10 μM 72 hours LDN-57444 significantly inhibited the colony formation ability of TD-NEPC cells PMC10897521

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Cardiac hypertrophy model Intraperitoneal injection 40 µg/kg Once daily for 2 weeks LDN-57444 significantly reversed cardiac hypertrophy and remodeling, indicating that UCHL1 is a potential therapeutic target for hypertrophic diseases. PMC7164950
Mice CCl4-induced liver fibrosis model intraperitoneal injection 0.4 mg/kg twice weekly for 4 weeks LDN-57444 significantly improved CCl4-induced liver fibrosis, reducing collagen deposition and the number of hepatic stellate cells PMC4866442
Mice NEPC, SCLC, and neuroblastoma xenograft models Intraperitoneal injection 5 mg/kg Once daily until the end of the experiment LDN-57444 significantly delayed tumor growth in NEPC, SCLC, and neuroblastoma xenograft models and reduced the expression of neuroendocrine markers PMC10897521
Mice Ang II-induced atrial fibrillation model Intraperitoneal injection 40 μg/kg Once daily for 3 weeks LDN-57444 significantly reduced Ang II-induced elevation of blood pressure, the inducibility and duration of AF, left atrial dilation, fibrosis, inflammation, and oxidative stress. LDN treatment also inhibited the activation of multiple signaling pathways (the AKT, ERK1/2, HIF-1α, and TGF-β/smad2/3 pathways) and the expression of CX43 protein in atrial tissues. PMC8075865

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.51mL

0.50mL

0.25mL

12.57mL

2.51mL

1.26mL

25.15mL

5.03mL

2.51mL

References

 

Historical Records

Categories